MA55093A - Méthodes et compositions pour le traitement du cancer - Google Patents

Méthodes et compositions pour le traitement du cancer

Info

Publication number
MA55093A
MA55093A MA055093A MA55093A MA55093A MA 55093 A MA55093 A MA 55093A MA 055093 A MA055093 A MA 055093A MA 55093 A MA55093 A MA 55093A MA 55093 A MA55093 A MA 55093A
Authority
MA
Morocco
Prior art keywords
cancer
compositions
treatment
methods
Prior art date
Application number
MA055093A
Other languages
English (en)
Inventor
Graeme Currie
Original Assignee
Fusion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fusion Pharmaceuticals Inc filed Critical Fusion Pharmaceuticals Inc
Publication of MA55093A publication Critical patent/MA55093A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA055093A 2019-03-01 2020-03-03 Méthodes et compositions pour le traitement du cancer MA55093A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812929P 2019-03-01 2019-03-01
US201962856216P 2019-06-03 2019-06-03
US201962907504P 2019-09-27 2019-09-27

Publications (1)

Publication Number Publication Date
MA55093A true MA55093A (fr) 2022-01-05

Family

ID=72235995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055093A MA55093A (fr) 2019-03-01 2020-03-03 Méthodes et compositions pour le traitement du cancer

Country Status (9)

Country Link
US (1) US20200277387A1 (fr)
EP (1) EP3930705A4 (fr)
AU (1) AU2020232695A1 (fr)
IL (1) IL285796A (fr)
MA (1) MA55093A (fr)
MX (1) MX2021010449A (fr)
SG (1) SG11202109336UA (fr)
WO (1) WO2020180898A1 (fr)
ZA (1) ZA202107139B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174904A1 (en) 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
EP4209216A4 (fr) * 2020-10-28 2024-10-02 Eisai R&D Man Co Ltd Composition pharmaceutique pour le traitement de tumeurs
WO2024104922A1 (fr) 2022-11-14 2024-05-23 Ascendis Pharma Growth Disorders A/S Procédé d'amélioration de la fonction musculaire squelettique
WO2024194300A1 (fr) 2023-03-20 2024-09-26 Ascendis Pharma Growth Disorders A/S Méthode de traitement d'une déformation thoraco-lombaire chez un sujet humain atteint d'achondroplasie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174904A1 (en) * 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
KR20170137717A (ko) * 2015-02-19 2017-12-13 바이오클린 테라퓨틱스, 인크. 암의 치료를 위한 방법, 조성물, 및 키트
US20180222983A1 (en) * 2017-02-06 2018-08-09 Bioclin Therapeutics, Inc. Methods, compositions, and kits for treatment of cancer

Also Published As

Publication number Publication date
EP3930705A1 (fr) 2022-01-05
WO2020180898A1 (fr) 2020-09-10
ZA202107139B (en) 2024-03-27
AU2020232695A1 (en) 2021-10-28
MX2021010449A (es) 2021-09-21
US20200277387A1 (en) 2020-09-03
SG11202109336UA (en) 2021-09-29
WO2020180898A8 (fr) 2020-10-29
IL285796A (en) 2021-10-31
EP3930705A4 (fr) 2023-09-06

Similar Documents

Publication Publication Date Title
MA43135A (fr) Compositions et méthodes pour le du traitement du cancer
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA49144A (fr) Polythérapies pour le traitement du cancer
MA56212A (fr) Compositions et méthodes de traitement du cancer
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA52780A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA52564A (fr) Inhibiteurs de kras g12c pour le traitement du cancer
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
MA50409A (fr) Polythérapies pour le traitement du cancer
MA48637A (fr) Polythérapies pour le traitement du cancer
MA45146A (fr) Dérivés de pyrazolopyridine pour le traitement du cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA51139A (fr) Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer
MA45675A (fr) Méthodes et compositions permettant le traitement du cancer
MA49576A (fr) Compositions et méthodes pour le traitement d'infections fongiques
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA52861A (fr) Méthodes et compositions pour le traitement de l'apnée du sommeil
MA51056A (fr) Compositions et méthodes pour le traitement d'affections métaboliques
MA53873A (fr) Compositions et procédés pour le traitement de la presbytie
MA44413A (fr) Composition pharmaceutique utilisée pour le traitement thérapeutique du cancer et ses complications